Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aroa Biosurgery's Enterprise Value is A$187.34 Mil.
Aroa Biosurgery's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.54 Mil. Therefore, Aroa Biosurgery's EV-to-EBIT ratio for today is 33.79.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Aroa Biosurgery's Enterprise Value is A$187.34 Mil.
Aroa Biosurgery's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$9.93 Mil. Therefore, Aroa Biosurgery's EV-to-EBITDA ratio for today is 18.88.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Aroa Biosurgery's Enterprise Value is A$187.34 Mil.
Aroa Biosurgery's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$86.60 Mil. Therefore, Aroa Biosurgery's EV-to-Revenue ratio for today is 2.16.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Aroa Biosurgery's Enterprise Value is A$187.34 Mil.
Aroa Biosurgery's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.68 Mil. Therefore, Aroa Biosurgery's EV-to-FCF ratio for today is 32.96.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Aroa Biosurgery (ASX:ARX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.54 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$9.93 Mil.
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$86.60 Mil.
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$8.79 Mil.
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was A$5.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery Enterprise Value Related Terms
Aroa Biosurgery Enterprise Value Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ARX vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Aroa Biosurgery's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of A$187.34 Mil mean?
Aroa Biosurgery (ASX:ARX) has a Enterprise Value of A$187.34 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Enterprise Value too high?
Aroa Biosurgery's current Enterprise Value is A$187.34 Mil. Overall, Aroa Biosurgery has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Enterprise Value compare to ABT and SYK?
Aroa Biosurgery's Enterprise Value of A$187.34 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Enterprise Value is A$187.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Enterprise Value is A$187.34 Mil. Aroa Biosurgery's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Enterprise Value is A$187.34 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Enterprise Value: A$187.34 Mil
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
63GF Score
Get the complete analysis for ASX:ARX
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
